Merrimack's Prospects Dim As MM-141 Fails Pancreatic Cancer Phase II Trial
Executive Summary
Merrimack Pharmaceuticals has ended development of its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.
You may also be interested in...
Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018
CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.